The mission of the Clinical Trials Transformation Initiative, a public-private partnership co-founded by the U.S. Food and Drug Administration and Duke University, is to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials. The Clinical Trials Transformation Initiative works collaboratively with key stakeholders, implements ''fit-for-purpose'' evidence-gathering projects, and develops actionable recommendations and tools to address the challenges faced by the clinical trials enterprise. In pursuit of its mission, The Clinical Trials Transformation Initiative follows an innovative and collaborative, five-step methodology: (1) state the problem and identify impediments to research, (2) gather evidence to identify gaps and barriers, (3) explore results by analyzing and interpreting findings, (4) finalize solutions by developing recommendations and tools, and (5) drive adoption through disseminating and implementing recommendations and tools. This article describes each step of the Clinical Trials Transformation Initiative's methodology, with a specific focus on describing the evidence-gathering activities.
Introduction
The Clinical Trials Transformation Initiative (CTTI), 1, 2 a public-private partnership co-founded by the U.S. Food and Drug Administration (FDA) and Duke University, was established in 2007 with the mission to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials. In pursuit of this mission, CTTI implements a multi-stakeholder approach to systematically address challenges that limit progress within the clinical trials enterprise and develops recommendations and tools in support of overcoming these challenges.
CTTI's work is grounded in three strengths ( Figure 1 ). First, CTTI is committed to the equal engagement of key stakeholders across four areas of the clinical trials enterprise: patients, government, academia, and industry. Second, CTTI employs scientifically rigorous approaches to identify evidence-based solutions to obstacles impeding the conduct of high-quality, efficient clinical trials. Third, this unique combination of stakeholder engagement and evidence-based solutions leads to the development of CTTI recommendations and tools that can result in real-word impact. These three strengths provide the foundation for the five interrelated steps that comprise CTTI's methodology ( Figure 2 ): (1) state the problem and identify impediments to research, (2) gather evidence to identify gaps and barriers, (3) explore results by analyzing and interpreting findings, (4) finalize solutions by developing recommendations and tools, and (5) drive adoption through disseminating and implementing recommendations and tools.
This article describes each step of CTTI's methodology, with a specific focus on the evidence-gathering activities.
Stating the problem
CTTI's methodology begins with identifying topics that challenge (e.g. investigator turnover 3 ) or promote (e.g. patient group engagement 4 ) the conduct of high-quality, efficient clinical trials. Topics are identified in various ways, but most are suggested by either the FDA or CTTI member organizations who represent CTTI's key stakeholder groups. Once CTTI identifies a topic, it uses member surveys and decision-making tools to systematically evaluate whether the topic is one that CTTI is uniquely positioned to address. Members also evaluate the topic's burden on-or benefit to-the clinical trials enterprise, its alignment with CTTI's mission, and the potential for project recommendations to transform practices, among other previously agreed-upon criteria.
Concept proposals are developed for the selected topics of interest through collaboration between CTTI staff and member organizations, using input from existing literature, key informants, and potential change agents. Concept proposals are approved by CTTI's Executive Committee 5 and move forward as CTTI projects. To initiate a CTTI project, CTTI appoints four to five project team leaders identified during the concept development process or nominated by member organizations. Team leaders are drawn from CTTI member organizations and are both subject-matter experts and passionate change agents interested in driving the strategic direction of the project. Team leaders and CTTI staff identify and recruit additional expert team members who represent various stakeholder groups. Project team members are engaged throughout all steps of the methodology and are critical to the success of CTTI projects. They provide their time and expertise in the development of actionable, evidence-based, and consensus-driven recommendations, and in the creation and sharing of CTTI-generated knowledge, tools, and resources to facilitate improvements in clinical trial quality and efficiency.
Team leaders and members work together with the project manager, the CTTI Social Science Team (SST) (described in the next section), and a ''Champion'' from the CTTI Executive Committee to draft a project plan. Project plans describe the specific issue to be addressed, overall project objectives, methods, timelines, anticipated products, predicted impact of the project, and a communications strategy. Team leaders and members provide the strategic direction for the plan, clarifying the issue, background, scope, and objectives, as well as identifying the anticipated audience(s) for the project products. Project managers support this effort by coordinating the team and tracking timelines and deliverables; the SST ensures the objectives are clear, logical, and attainable. CTTI disseminates the project plan to member organizations for review at the beginning of the project, and the plan is then refined over the course of the entire project with input from the full project team. This collaborative and iterative development process ensures that the project plan addresses the most critical and actionable issues, will yield important change, and is meaningful to a broad range of stakeholders.
Gathering evidence
During this phase of CTTI's methodology, data are gathered that will be used by the project team to inform recommendations and tools. Currently, social scientists are embedded within CTTI, and the SST leads the evidence-gathering phase in collaboration with project teams. Members of the SST include doctorate-and masters-level social scientists, research assistants, and one statistician. Pairing subject matter (the project team) and methodology experts (the SST) uniquely positions CTTI to identify the most relevant and pressing issues that impede the quality and efficiency of clinical trials, and to investigate those issues using scientifically rigorous approaches.
CTTI follows a standard, systematic process to develop its evidence-gathering activities ( Figure 3 ). Although each project is distinct in its approach and tailored to meet its overall objectives, CTTI follows a similar path for most projects in its portfolio. The following section describes the steps of the evidencegathering activities.
Background and significance
Planning for evidence-gathering activities typically begins with a thorough discussion among the project team members about the issue's background and significance. This allows members to share their expertise on the project topic, as well as for the SST to share detailed literature reviews to ensure that CTTI's research builds upon current knowledge.
Study objectives
Next, the project team works with the SST to develop objectives specific to the evidence-gathering phase. In drafting these objectives, project team members discuss the type of data they believe are needed to best understand the issue (e.g. the Mobile Clinical Trials Stakeholder Perceptions project objectives included site investigators' perceptions on budgetary, training, or other support needs necessary to adequately prepare for and implement mobile clinical trials) 6 and to inform recommendations and tools (e.g. provide recommendations to research sponsors on the needs of site investigators to conduct high-quality, efficient mobile clinical trials).
Study design
The SST next identifies a study design that best aligns with the evidence-gathering objectives. Because CTTI is at the forefront of tackling issues affecting the conduct of clinical trials, its evidence-gathering activities are predominantly exploratory and focus on collecting data to better understand the nuances of a particular issue and inform the development of recommendations and tools. CTTI uses both qualitative and quantitative descriptive study designs; 7 however, qualitative designs are used most often as such studies gather rich, in-depth information about a particular phenomenon.
Where appropriate, CTTI uses mixed-method study designs as well as multi-phase study designs, in which data from an initial phase of evidence gathering informs subsequent evidence gathering. For example, for the Mobile Clinical Trials Project on the Scientific and Technological Issues Surrounding the Use of Mobile Devices in Clinical Trials, 8 in-depth interviews were conducted with investigators and sponsors, followed by another round of in-depth interviews with device manufacturers, data security experts, and statisticians to fill knowledge gaps identified during the analysis of the initial data.
Study sample and selection
Study planning then shifts to the identification of study populations and sampling strategies. For CTTI's qualitative studies, the project team first develops eligibility criteria based on the type of experiences participants must have had to inform evidence-gathering objectives. Participants are then purposefully selected based on those eligibility criteria. 9 For CTTI-led surveys, both Figure 3 . The evidence-gathering development process.
probability and non-probability sampling strategies are used. For example, CTTI used a probability sampling strategy in their Investigator Community project 3 to randomly select and invite participants from the FDA's Bioresearch Monitoring Information System database to participate in a CTTI survey on investigator turnover. 10 Non-probability sampling strategies, however, are used more frequently because a definitive group of key informants to sample (e.g. all investigators who conduct pediatric antibacterial drug clinical trials) often does not exist. In these situations, CTTI frequently collaborates with patient advocacy groups and professional organizations to identify potential participants and send survey invitation emails. For example, as part of CTTI's Antibacterial Pediatric Trials project, 11 CTTI collaborated with the American Academy of Pediatrics (AAP) to identify the most relevant member section groups of AAP in which to distribute an invitation email and survey for community providers and investigators on perceived barriers to pediatric antibacterial clinical trials. In addition, project team members and individuals from CTTI member organizations use their expert knowledge of a given topic to identify and recruit potential participants. CTTI has also used recruitment firms and patient databases to identify and recruit patients.
Data collection methods
Discussions about study populations and sampling strategies usually intertwine with considerations on the method(s) of data collection that are most appropriate for the project. CTTI uses a variety of data collection methods. CTTI typically uses qualitative data collection methods, such as in-depth interviews, when a little information is known about an issue. Interviews are often one-on-one but group interviews are also conducted, particularly when expertise surrounding an issue is dispersed among a small group of people within an organization. CTTI uses quantitative methods and primarily structured surveys, when it wants to measure and describe the variation of a phenomenon. For example, as part of the Antibacterial Pediatric Trials project, 11 CTTI identified the most problematic barriers for investigators of pediatric antibacterial clinical trials by quantifying the perceived severity of potential barriers.
Other methods such as focus group discussions, systematic literature reviews, online pile sorts, 12 and vignettes 13 have been used. For example, vignettes were used in the CTTI formative research study on hospital-acquired and ventilator-associated bacterial pneumonia clinical trials to understand perceptions of key stakeholders on the use of an early enrollment strategy. 14 CTTI uses a systematic question mapping process to develop survey questionnaires and qualitative question guides: evidence-gathering objectives are deconstructed into topical domains, each of which is further characterized into individual questions. The SST and project team members work hand-in-hand to develop data collection instruments, brainstorming content, and ensuring alignment between questions asked and evidence-gathering objectives. The project team also provides regular feedback on the data collection instruments as they are being developed. When necessary, CTTI conducts formative research to inform survey development.
CTTI data collection instruments are usually pretested. For qualitative question guides, pre-test interviews are conducted with appropriate individuals from CTTI member organizations, and modifications are made to the question guides, as needed. For quantitative surveys, CTTI has conducted cognitive interviews 15 to evaluate survey content. For example, as part of the Mobile Clinical Trials Stakeholder Perceptions project, 6 cognitive interviews were conducted with numerous patients similar to those in the future study to determine whether proposed survey questions and response categories were interpreted as intended and understandable, or if any modifications were needed.
All in-depth interviews and focus groups are digitally audio-recorded, with participants' permission (if participants decline audio recording, the SST takes detailed notes). Verbatim transcripts are produced, following a structured transcription protocol. 16 Data collection for CTTI projects is typically managed by the SST, whose members schedule and conduct all qualitative interviews, and facilitate survey distribution.
At the conclusion of the planning phase for evidence-gathering activities, the SST leads protocol development and submits all protocols for review by the Duke University Health System Institutional Review Board. Protocols typically receive a determination of exempt status.
Data analysis strategies
The SST typically conducts data analysis. Applied thematic analysis 17 is used to formally analyze all qualitative data. This analysis method usually involves structural, deductive (a priori), and/or inductive (thematic) coding 17, 18 of verbatim interview and focus group transcripts using NVivo, a qualitative data analysis software program, 19 inter-coding reliability checks, and memo writing on themes and sub-themes for each research topic. To describe and analyze survey data, descriptive statistics and tests of association (e.g. chisquare analyses) are most frequently used.
The SST also prepares reports to describe data obtained in the evidence-gathering phase, which the project teams use to inform recommendations related to the project topic. Manuscripts summarizing data collected during the evidence-gathering phase are also prepared and submitted to peer review journals. In addition, CTTI sends aggregated summaries of evidence-gathering findings to interested participants. De-identified quantitative data sets are made publicly available on CTTI's website. 2 
Exploring results and finalizing solutions
Project teams carefully review the data from evidencegathering activities, usually during a full day in-person meeting. These meetings provide opportunities for team members to identify insights, test previous assumptions, and describe their interpretations of the data within the context of the larger clinical trials enterprise. As research is an iterative process, new topics can emerge from the data that lead to the need for further exploration and additional data collection. These new topics may be explored with the same group of stakeholders or require that new stakeholders be identified and included in future data collection activities. In these situations, team members consider the type of additional information needed, its potential to inform understanding of barriers and potential solutions to existing problems, and who best can provide the needed information.
After the project team fully dissects the collected data, a multi-stakeholder meeting is held with an expanded group of expert representatives of key stakeholder groups. Grounded in the belief that all stakeholders should have an equal voice in developing solutions, CTTI creates a forum for open and honest dialog geared toward using the evidence gathered to develop actionable solutions. Project team members work together to set meeting objectives, to develop the agenda and invited participant list, and to ensure a wide range of voices and opinions will be part of the slate of presenters and in the group discussion. During the typically 1.5-day-long meeting, recognized experts are invited to serve as moderators and panelists and to actively share their experiences in the field, while team members present data from the evidence-gathering activities. Participants discuss possible solutions that serve as the basis for project recommendations and tools. Expert meeting discussions may also lead to refining ideas that result in new problem statements and additional data to gather. At each stage, CTTI recognizes and appreciates this iterative process as part of its comprehensive methodology, as depicted by the dotted line traveling upward in the methodology graphic (Figure 2) .
After the project team determines that the evidence-gathering objectives have been met and no major gaps in evidence remain, it develops project recommendations and supportive tools. CTTI aims to develop recommendations that are actionable, evidence-based, concise, easily digestible by an external audience, and consensus-driven. To this end, it follows an iterative development process. First, team members use the data from the evidence-gathering activities and input from the expert meeting to draft and propose project recommendations and tools. Next, the project team seeks and incorporates input from the Executive Committee Champion, CTTI leadership, CTTI members, and, for recently released recommendations, an ad hoc committee comprising change agents independent of the project team. Refinement of the recommendations and tools continues until the team reaches consensus.
Prior to dissemination, the CTTI member organizations review all project recommendations and tools and provides constructive feedback and edits. Finally, the CTTI Executive Committee considers and approves the recommendations and tools.
Driving adoption
Once a set of recommendations and tools are approved, they are made freely available on the CTTI website 2 and are publicly promoted to key stakeholders through a variety of channels (e.g. webinars, public presentations, and publications). CTTI also works with its member organizations and other interested parties to facilitate adoption of these resources.
For some previously completed projects, additional issues emerged during member discussions that developed into new CTTI projects, referred to as ''follow-on'' projects. For example, for CTTI's Monitoring project, 20 additional methods for improving the monitoring of clinical trials emerged during the dissemination and adoption phase of the project. During discussions, team members recognized that opportunities to improve clinical trial quality exist long before monitoring is conducted during the trial. As a result, the Quality by Design (QbD) project was formed and implemented. 21 CTTI also uses case studies to share concrete examples of how its recommendations have been adopted, providing a roadmap that others may follow to integrate CTTI recommendations and tools into their programs. As an example, a case study approach was used to explore challenging safety reporting scenarios as part of the CTTI IND Safety Advancement Project. 22, 23 CTTI-developed case studies are often shared through CTTI's websites, media outreach, social media, blogs, educational webinars, and workshops. 24 An important component of driving adoption is to measure the impact of CTTI's work. Impact can be measured by changes in the practices and policies of organizations that design, conduct, regulate, and benefit from clinical trials. Examples of CTTI's impact are described in greater detail by Tenaerts et 
Looking forward
CTTI is and will remain focused on convening multistakeholder teams to identify and address the plethora of challenges facing clinical trials. The synergistic effect of bringing together key stakeholders is leveraged throughout the CTTI methodology. This enables CTTI to identify the most pressing issues facing new medical product development, recruit key informants and gather evidence using fit-for-purpose methodologies, discuss potential solutions that will benefit all stakeholders, and develop tailored and actionable recommendations. By working collaboratively to address the challenges the clinical trials enterprise continues to face, CTTI aims to improve the quality and efficiency of clinical trials, helping to make new medical products available to patients who need them.
